Matthew S Block1, Matthew J Maurer2, Krista Goergen2, Kimberly R Kalli3, Courtney L Erskine4, Marshall D Behrens4, Ann L Oberg2, Keith L Knutson5. 1. Department of Oncology, Mayo Clinic, Rochester, MN, United States; Department of Immunology, Mayo Clinic, Rochester, MN, United States. Electronic address: block.matthew@mayo.edu. 2. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, United States. 3. Department of Oncology, Mayo Clinic, Rochester, MN, United States. 4. Department of Immunology, Mayo Clinic, Rochester, MN, United States. 5. Vaccine and Gene Therapy Institute, Port Saint Lucie, FL, United States; Department of Immunology, Mayo Clinic, Rochester, MN, United States.
Abstract
OBJECTIVES: Inflammation is a common feature of epithelial ovarian cancer (EOC), and measurement of plasma markers of inflammation might identify candidate markers for use in screening or presurgical evaluation of patients with adnexal masses. METHODS: Plasma specimens from cohorts of 100 patients with advanced EOC (AJCC Stage III and IV), 50 patients with early stage EOC (Stage I and II), and 50 patients with benign surgical conditions were assayed for concentrations of multiple cytokines, toll-like receptor agonists, and vascular growth factors via ELISA and electrochemiluminescence. Immune proteins were then analyzed for association with EOC. Differences in plasma protein levels between benign, early, and advanced EOC patient groups were assessed with and without adjustment for plasma cancer antigen 125 (CA-125) levels. RESULTS: Out of 23 proteins tested, six-including interferon gamma (IFNγ), interleukin 6 (IL-6), IL-8, IL-10, tumor necrosis factor alpha (TNFα), and placental growth factor (PlGF)-were univariately associated with EOC (all p<0.005), and one-IL-6-was associated with early stage EOC (p<0.0001). Heat shock protein 90kDa beta member 1 (HSP90B1, gp96) was associated with EOC and early stage EOC with borderline statistical significance (p=0.039 and p=0.026, respectively). However, when adjusted for (CA-125), only HSP90B1 independently predicted EOC (p=0.008), as well as early stage EOC (p=0.014). CONCLUSIONS: Multiple plasma cytokines, including IFNγ, IL-6, IL-8, IL-10, TNFα, PlGF, and HSP90B1 are associated with EOC. Of these, HSP90B1 is associated with EOC independent from the biomarker CA-125.
OBJECTIVES:Inflammation is a common feature of epithelial ovarian cancer (EOC), and measurement of plasma markers of inflammation might identify candidate markers for use in screening or presurgical evaluation of patients with adnexal masses. METHODS: Plasma specimens from cohorts of 100 patients with advanced EOC (AJCC Stage III and IV), 50 patients with early stage EOC (Stage I and II), and 50 patients with benign surgical conditions were assayed for concentrations of multiple cytokines, toll-like receptor agonists, and vascular growth factors via ELISA and electrochemiluminescence. Immune proteins were then analyzed for association with EOC. Differences in plasma protein levels between benign, early, and advanced EOC patient groups were assessed with and without adjustment for plasma cancer antigen 125 (CA-125) levels. RESULTS: Out of 23 proteins tested, six-including interferon gamma (IFNγ), interleukin 6 (IL-6), IL-8, IL-10, tumor necrosis factor alpha (TNFα), and placental growth factor (PlGF)-were univariately associated with EOC (all p<0.005), and one-IL-6-was associated with early stage EOC (p<0.0001). Heat shock protein 90kDa beta member 1 (HSP90B1, gp96) was associated with EOC and early stage EOC with borderline statistical significance (p=0.039 and p=0.026, respectively). However, when adjusted for (CA-125), only HSP90B1 independently predicted EOC (p=0.008), as well as early stage EOC (p=0.014). CONCLUSIONS: Multiple plasma cytokines, including IFNγ, IL-6, IL-8, IL-10, TNFα, PlGF, and HSP90B1 are associated with EOC. Of these, HSP90B1 is associated with EOC independent from the biomarker CA-125.
Authors: Jason E Dodge; Allan L Covens; Christina Lacchetti; Laurie M Elit; Tien Le; Michaela Devries-Aboud; Michael Fung-Kee-Fung Journal: Gynecol Oncol Date: 2012-04-06 Impact factor: 5.482
Authors: Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos Journal: N Engl J Med Date: 2003-01-16 Impact factor: 91.245
Authors: G Scambia; U Testa; P Benedetti Panici; E Foti; R Martucci; A Gadducci; A Perillo; V Facchini; C Peschle; S Mancuso Journal: Br J Cancer Date: 1995-02 Impact factor: 7.640
Authors: Purushottam Lamichhane; Lavakumar Karyampudi; Barath Shreeder; James Krempski; Deborah Bahr; Joshua Daum; Kimberly R Kalli; Ellen L Goode; Matthew S Block; Martin J Cannon; Keith L Knutson Journal: Cancer Res Date: 2017-10-09 Impact factor: 12.701
Authors: Stefanie Aust; Thomas Knogler; Dietmar Pils; Eva Obermayr; Alexander Reinthaller; Lisa Zahn; Ilja Radlgruber; Marius Erik Mayerhoefer; Christoph Grimm; Stephan Polterauer Journal: PLoS One Date: 2015-10-12 Impact factor: 3.240
Authors: Kristin L M Boylan; Kate Geschwind; Joseph S Koopmeiners; Melissa A Geller; Timothy K Starr; Amy P N Skubitz Journal: Clin Proteomics Date: 2017-10-10 Impact factor: 3.988